INDEX

A
Adverse drug reaction, reporting, XVII, XXI, 17, 29, 72
Adverse event, XVII, 16, 17, 21, 30, 38, 52, 74, 92, 98, 104, 107, 109, 111, 120, 134, 143, 157, 169, 175
Audit, XVII, 21, 67, 77, 81, 85, 88, 92, 102, 103, 104, 116, 142, 150, 174
Audit, Investigator site, 79
Audit, sponsor, 86
Audit, IRB, 88, 91, 110
Audit certificate, XVII, 23, 85
Audit trail, XVII, 8, 23, 37, 85
Audit report, XVII, 22, 23, 116, 174
Auditor, 22, 35, 37, 80, 88, 96, 173

B
Belmont Report, 16, 233
BIMO Inspections, 69

C
CRF, Case Report Forms, XVIII, 9, 20, 21, 25, 37, 107, 108, 111, 113, 114, 115, 137, 139, 141, 144, 150, 169, 171, 172, 174
Clinical Hold, 49, 125, 126, 147
Clinical Trial Agreement, 10, 12, 20
Clinical Trial Coordinator, 7, 11, 79, 86, 116, 119, 132, 134, 137, 141, 144
Contract Research Organization (CRO), XVII, 7, 18, 68, 69, 70, 75, 79, 83, 85, 86, 87, 89, 96, 105, 120, 150

D
Declaration of Helsinki, 2, 16, 25, 30, 33, 74, 82, 97, 131, 154, 155
Disqualification of investigators, 58, 67, 124, 125, 166
Disqualification of IRBs, 65, 66

E
Ethics Comittees, xix, 42

F
FDA bioresearch monitoring program, XV, 53, 67, 69, 71, 93, 122
FDA audit procedures, 104
For a cause inspection “directed”, 68, 81, 84
Form 1571, 6, 53, 77, 83, 87, 112, 115
Form 482, 88, 103, 104, 119
Form 483, 91, 116, 119, 149
Fraud and misconduct, 68, 76, 78, 107, 169, 173

G
GCP Good Clinical Practice, 1, 2, 3, 5, 42, 51, 53, 54, 67, 69, 71, 74, 77, 80, 121, 122, 131, 138, 141, 151, 155, 179
GCP compliance, XIV, 2, 52

I
IDE Investigational Device Exemption, 86, 91
IND Investigational New Drug Application, 58, 72, 74, 82, 83, 86, 91, 126, 152, 153, 161, 175
Informed consent, Patient Information and Consent form, 20, 25, 26, 27, 33, 36, 53, 55, 56, 57, 61, 62, 63, 64, 72, 74, 85, 89, 93, 94, 96, 98, 100, 104, 105, 108, 109, 110, 129, 146, 154, 158, 159, 161, 162, 164, 171, 173, 175
Informed consent, elements, 34
Informed consent, emergency situations, 36
Informed consent, legal representative, 36
INDEX

Institutional Review Board (IRB) SOPs - standard operational procedures, 28
International Conference on Harmonization-ICH, XIII, XV, XVI, XVII, 3, 17, 24, 67, 179
Investigator brochure, XIX, XXI, 11, 14, 17, 20, 25, 42, 43, 55, 85, 89, 92, 99, 107, 110, 112, 154, 181, 185, 186, 188, 190, 191, 197, 201, 202, 205, 208, 211
Investigator brochure, content, 212
Investigators selection, 10
Investigators site personnel qualification, 10, 26, 29, 95, 112, 114, 134, 175, 179, 188, 190, 218
Inspection, investigator site, 79, 92, 101
Inspection CRO, 79
Inspections, international sites, 115
Inspection IRB, 88

M
Monitor, monitoring, 17, 18, 19, 53, 63, 68, 74, 79, 85, 93, 105, 107, 111, 127, 139, 140, 143, 148, 149, 150, 151, 180, 183, 185, 190, 198, 201, 203, 204, 206, 207, 210, 211, 215, 219, 221, 223
monitoring procedures, 21, 206
Monitors qualifications, 204
Monitors responsibilities, 19

N
NAI, 68, 69, 70, 71, 90
NIDPOE letter, 124
Nuremberg code, XVI, 231

P
Phases in clinical research, 9

Q
Quality Assurance, 1, 4, 6, 7, 21, 23, 41, 52, 53, 77, 79, 80, 81, 87, 88, 107, 123, 148, 150, 169, 185, 198, 207, 211

S
Serious Adverse Event (SAE), XX, 85, 89, 92, 144, 145, 148, 152, 169, 186, 197
Source data/document, 6, 9, 18, 20, 37, 40, 41, 79, 85, 93, 96, 97, 102, 106, 107, 108, 114, 120, 134, 139, 140, 141, 151, 152, 156, 169, 171, 174, 181, 185, 190, 196, 198, 203, 204, 205, 206, 211, 215, 221
Sponsor, 1, 4, 5, 6, 9, 48, 50, 69, 70, 76, 86, 87, 88, 89
Sponsor responsibilities, 6, 54
Standard Operational Procedures (SOP), 4, 5, 6, 8, 12, 18, 21, 22, 23, 28, 29
Study oriented inspections, 101

T
Training, GCP, SOP, 18, 19, 20, 22, 29, 30

W
Warning letter, 71, 121, 129